Given the promising results treating smaller, vascularised tumours (VCAM-1 & lymphoid targeting therapies) compared to the relative difficulty with melanin targeted melanoma treatments, i.v. administered mAb targeted therapy appears to be profoundly influenced by the tumour environment. Here, VCAM1 is linked to neoplasm.